

**PRELIMINARY ESTIMATE - S. 469, the Affordable and Safe Prescription Drug Importation Act (as introduced)**

(July 31, 2017)

Prepared for the Ranking Member of the Senate Budget Committee

(Millions of dollars, by fiscal year)

	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2017-2022	2017-2027
<b>CHANGES IN DIRECT SPENDING</b>													
Estimated Budget Authority	0	0	0	-28	-174	-434	-703	-737	-915	-1,014	-1,104	-635	-5,107
Estimated Outlays	0	0	0	-28	-174	-436	-706	-741	-917	-1,014	-1,104	-637	-5,119
<b>CHANGES IN REVENUES</b>													
Total Changes in Revenues	0	0	0	8	45	125	228	292	324	343	359	178	1,725
<i>On-budget</i>	0	0	0	7	34	96	176	229	253	267	278	137	1,340
<i>Off-budget</i>	0	0	0	1	11	29	51	63	71	76	81	42	384
<b>DECREASES IN DEFICITS FROM CHANGES IN DIRECT SPENDING AND REVENUES</b>													
Net Decrease in the Deficit	0	0	0	-36	-219	-561	-934	-1,033	-1,241	-1,357	-1,463	-816	-6,843
<i>On-budget</i>	0	0	0	-35	-208	-532	-883	-970	-1,170	-1,281	-1,382	-774	-6,459
<i>Off-budget</i>	0	0	0	-1	-11	-29	-51	-63	-71	-76	-81	-42	-384

Notes: Estimates are relative to CBO's January 2017 baseline; Components may not sum to totals because of rounding.

The bill, as introduced on February 28, 2017, would expand the Food and Drug Administration's regulatory authority surrounding importation of prescription drugs. The legislation would also permit pharmacies, wholesalers, and individuals (for personal use) to import prescription drugs into the United States under certain new conditions from selected countries. The bill would also affect spending subject to appropriation. CBO has not completed that analysis.